利肝隆联合异甘草酸镁治疗自身免疫性肝炎患者疗效及其对血清趋化因子水平的影响*

doi:10.3969/j.issn.1672-5069.2020.06.016

Abstract

Abstract: Objective The aim of this study was to analyze Liganlong, a herbal conpound, and magnesium isoglycyrrhizate combination how to mitigates liver injury in patients with autoimmune hepatitis (AIH). Methods 122 patients with AIH were admitted to Department of Infectious Diseases and Gastroenterology in our hospital between July 2017 and May 2019, and were divided into control group and observation group by computer-generated randomized numbers, with 61 cases in each. The patients in the control group were treated by intravenous infusion of magnesium isoglycyrrhizinate and those in the observation group were treated with Liganlong tablets orally at the basis of medicine in the control group. The regimen in both groups lasted for 3 months. Serum chemotactic factor (CF) and immunoglobulin (Ig) levels were detected. Results At the end of treatment, serum alanine aminotransferase (ALT) level in the observation group was (46.3±13.7) U/L, significantly lower than [(82.5±14.2) U/L, P<0.05] and serum aspartate aminotransferase (AST) level was (45.5±14.3) U/L, significantly lower than [(66.7±16.8) U/L, P<0.05] in the control group; serum CF-8 level was (10.6±2.1)pg/mL, significantly lower than 【(15.8±3.3)pg/mL, P<0.05】, serum CF-2 level was (13.5±1.0)pg/mL, significantly lower than 【(19.0±1.3)pg/mL, P<0.05】, and serum CF-9 level was (12.1±1.7)pg/mL, significantly lower than 【(15.8±1.4)pg/mL, P<0.05】; serum IgG level was (1313.1±191.0)mg/L, significantly lower than 【(1816.4±311.6)mg/L, P<0.05】, serum IgM level was (506.2±151.3)mg/L, significantly lower than 【(814.1±225.1)mg/L, P<0.05】,and serum IgA level was (509.1±128.6)mg/L, significantly lower than 【(749.7±231.9)mg/L, P<0.05】 in the control; during the treatment, the incidence of side effects in the combination group was 18.0%, not significantly different as compared to 4.9% in the control group (P>0.05). Conclusion The steroid free treatment, e.g. Liganlong, a herbal medicine, and magnesium isoglycyrrhizinate combination, in patients with autoimmune hepatitis is a real viable option to obtain remission, that might be related to the inhibition of humoral immunity, reduction of serum CF-8 , CF-9 and CF-2 levels and obviously improvement of liver functions.

Key words: Autoimmune hepatitis, Liganlong,herbal medicine, Magnesium isoglycyrrhizinate, Humoral immunity, Chemokine-8, Therapy

Wang Yu, Wang Nan, Wang Qiaoxia, et al. Liganlong and magnesium isoglycyrrhizate combination mitigates liver injury via inhibiting humoral immunity in patients with autoimmune hepatitis[J]. Journal of Practical Hepatology, 2020, 23(6): 821-824.

References

[1] 赵素贤, 张玉果, 谭普芳, 等.药物诱导的自身免疫性肝炎与药物性肝损伤的临床特征对照研究.中华肝脏病杂志, 2016, 24(4): 302-306.
[2] 张洪文, 刘会敏, 林睿, 等.自身免疫性肝炎治疗应答不良患者的临床特点分析.中华肝脏病杂志, 2017, 25(10): 755-759.
[3] Giuseppe M. Steroid free treatment in autoimmune hepatitis: is azathioprine monotherapy truly a viable option to obtain remission. J Pediatr, 2019, 210(8): 56-58.
[4] Gao MX, Li XL, He LL, et al. Diammonium glycyrrhizinate mitigates liver injury via inhibiting proliferation of NKT cells and promoting proliferation of Tregs. Drug Des Devel Ther, 2019, 13(7): 98-100.
[5] 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 自身免疫性肝炎诊断和治疗共识(2015). 中华传染病杂志, 2016, 34(4): 193-208.
[6] 龙梅, 王丽旻, 朱莉, 等. 自身免疫性肝炎患者临床和肝组织病理学特征.实用肝脏病杂志, 2020, 23(1): 142-143.
[7] Peters MG. Long-term use of azathioprine in the management of autoimmune hepatitis.Nat Rev Gastroenterol Hepatol, 2019, 15(5): 53-56.
[8] Shi HJ,Song HB,Gao Q, et al. Combination of oxymatrine and diammonium glycyrrhizinate significantly mitigates mice allergic contact dermatitis induced by dinitrofluorobenzene. Exp Biol Med, 2019, 244(13): 78-81.
[9] Zeman MV, Hirschfield GM. Autoantibodies and liver disease: uses and abuses. Can J Gastroenterol, 2016, 24(4): 225-231.
[10] Anna P, Malgorzata SP, Malgorzata P. Evaluation of the effectiveness of treatment with prednisone and azathioprine of autoimmune hepatitis in children. Prz Gastroenterol, 2016, 11(1): 18-23.
[11] Kalinskabienias A, Jakubowska B, Kowalewski C, et al. Measuring of quality of life in autoimmune blistering disorders in Poland. validation of disease specific autoimmune bullous disease quality of life(abqol) and the treatment autoimmune bullous disease quality of life (tabqol) questionnaires. Adv Med Sci, 2017, 62(1): 92-96.
[12] Chaouali M, Fernandes V, Ghazouani E, et al. Association of stat4, TGFβ1, sh2b3 and ptpn22 polymorphisms with autoimmune hepatitis. Exp Mol Pathol, 2018, 105(3): 279-284.
[13] Rizvi S, Gawrieh S. Autoimmune hepatitis in the elderly: diagnosis and pharmacologic management. Drugs Aging, 2018, 35(7): 589-602.
[14] Yang Q, Wang J, Liu R, et al. Amelioration of concanavalin A induced autoimmune hepatitis by magnesium isoglycyrrhizinate through inhibition of cd4(+)cd25(-)cd69(+)subset proliferation. Drug Des Devel Ther, 2016, 25(10): 443-53.
[15] Tan QY, Hu Q, Zhu SN, et al. Licorice root extract and magnesium isoglycyrrhizinate protect against triptolide-induced hepatotoxicity via up-regulation of the nrf2 pathway. Drug Deliv, 2018, 25(1): 1213-1223.
[16] Sun W, Wu HY, Chen S. Influence of tbx21 t-1993c varianton autoimmune hepatitis development by yin-yang 1 binding. World J Gastroenterol, 2017, 23(48): 8500-8511.
[17] Buechter M, Manka P, Heinemann FM, et al. Potential triggering factors of acute liver failure as a first manifestation of autoimmune hepatitis-a single center experience of 52 adult patients. World J Gastroenterol, 2018, 24(13): 1410-1418.
[18] 张攀, 刘涛, 王芳芹, 等. 异甘草酸镁对小鼠放射性肺纤维化的改善作用及其机制的初步研究. 中国药理学通报, 2017, 33(2): 201-206.
[19] Ma D, Zhang J, Zhang Y, et al. Inhibition o f myocardial hypertrophy by magnesium isoglycyrrhizinate through the tlr4/nf-kb signaling pathway in mice. Int Immunopharmacol, 2018, 55(8): 237-244.
[20] Zhai XF, Wang SL, Zhu MY, et al. Antiviral effect of lithium chloride and diammonium glycyrrhizinate on porcine deltacoronavirus in vitro. Pathogens, 2019, 8(3): 56-58.
[21] Sebode M, Hartl J, Vergani D, et al. Autoimmune hepatitis: from current knowledge and clinical practice to future research agenda. Liver Int, 2018, 38(1): 15-22.

Liganlong and magnesium isoglycyrrhizate combination mitigates liver injury via inhibiting humoral immunity in patients with autoimmune hepatitis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhou Xinmin, Ding Xiaopeng. Highlights of conventional supporting therapy for patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(1): 4-6.
[2]	Liu Qi, Hao Jiqing. Immunotherapy of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2021, 24(1): 7-9.
[3]	Zheng Zhiheng, Li Weiyun, Hui Zhenyu,et al. Serological and virological response topegylated interferon α-2a and entecavir combination in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2021, 24(1): 19-22.
[4]	Lin Jinxiang, Yang Keli. Comparison of response toPEG-IFNα-2a or PEG-IFNα-2b in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2021, 24(1): 27-30.
[5]	Fan Bingdong, Zhang Guohua, Wang Jun. An observation of clinical efficacy of sofosbuvir/vipatavir and ribavirin combination in the treatment of patients with chronic hepatitis C [J]. Journal of Practical Hepatology, 2021, 24(1): 31-34.
[6]	Yang Xiaodong,Jia Ting,Zhang Xiuling, et al. Short-term efficacy of danorevir and peginterferon-α in the treatment of patients with genotype 3 infected chronic hepatitis C [J]. Journal of Practical Hepatology, 2021, 24(1): 35-38.
[7]	Wei Xiuqin, Yan Xiaoxia, Shi Guorong, et al. Short-termefficacy of atorvastatin and tiopronin combination in the treatment of patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2021, 24(1): 47-50.
[8]	Li Zhao, Huang Zansong , Li Fan. Application of fenofibrate and bicyclol combination in treatment of patients with non-alcoholic fatty liver diseases and changes of hepatic PPARγ₂ [J]. Journal of Practical Hepatology, 2021, 24(1): 59-62.
[9]	Chen Jinyu, Guo Xiaoxia, Zhong Xiaoni. Efficacy of bifidobacterium triple viable capsuleand metformin in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 63-66.
[10]	Chen Yanping, Huang Shaoqiang,Deng Xin ,et al. Short-term efficacy of tiopronin and polyene phosphatidylcholine combination in treatment of patients with alcoholic liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 67-70.
[11]	Cai Yu, Wang Mengchun, Qiu Xinping, et al. Improvement of liver function and subsiding jaundice by compound glycyrrhizin and adenosylmethionine succinate in the treatment of patients with alcoholic hepatitis [J]. Journal of Practical Hepatology, 2021, 24(1): 71-74.
[12]	Wu Chang,Tian Yuan,Liu Hongyan. Short-term efficacy of live clostridium butyricum in assisting tiopronin and metadoxine in treatment of patients with alcoholic liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 75-78.
[13]	Li Qingling, He Shuguang, Yi Xiaoming, et al. Changes of peripheral blood lymphocyte PD-1 and PD-L1 expression in patients with autoimmune hepatitis receiving tripterygium wilfordii polyglycosides and magnesium iso-glycyrrhizate [J]. Journal of Practical Hepatology, 2021, 24(1): 79-82.
[14]	Zeng Jiao, Guo Guihai. Efficacy and safety of polyethylene glycol and lactulose in the treatment of patients with hepatic encephalopathy:a Meta-analysis [J]. Journal of Practical Hepatology, 2021, 24(1): 99-102.
[15]	Fan Jing, Xu Jing, Yuan Xue. Combination of rifaximin and lactulose improves clinical efficacy and mortality in hepatitis B cirrhotic patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2021, 24(1): 103-106.